相关实验视频
Updated: Feb 17, 2026

12:38
Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
Published on: November 6, 2021
3.1K
富拉诺库马林衍生物抑制MRGPRX2-介导的伪过敏
Wen Yang1, Xin Jia2, Wenyu Yang1
1School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Bioorganic & medicinal chemistry letters
|February 15, 2026
概括
新型富拉诺库马林衍生物XAT-13和XAT-14显示出作为Mas相关G蛋白结合受体X2 (MRGPRX2) 抗剂的前景. 这些化合物通过抑制巨细胞脱粒化来有效抑制伪过敏反应,为新的抗炎疗法提供了潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 药用化学 医学化学
背景情况:
- 与Mas相关的G蛋白结合受体X2 (MRGPRX2) 是伪过敏疾病的关键目标.
- 开发MRGPRX2抗剂具有显著的治疗潜力,但目前还没有批准的药物.
- 帝国素 (Imperatorin) 是一种 furancoumarin,此前已被确定为主要的MRGPRX2抗剂.
研究的目的:
- 合成和评估十四种子胺衍生物作为潜在的MRGPRX2对手.
- 为了研究这些新型化合物的抗伪过敏作用.
- 探索衍生品和MRGPRX2.2之间的结构-活动关系.
主要方法:
- 合成十四种子胺衍生物.
- 在体外和体内实验,以评估抗伪过敏活性.
- 分子对接研究以预测与MRGPRX2的结合相互作用2.
主要成果:
- 化合物XAT-13和XAT-14显示显著的剂量依赖抑制化合物48/80诱导的大细胞脱粒化.
- 分子对接表明,XAT-13和XAT-14可能与化合物48/80结合到相同的部位.
- 这些化合物在MRGPRX2-介导的疾病中表现出早期的潜力.
结论:
- XAT-13和XAT-14是与MRGPRX2相关的杆细胞脱粒化的有效抑制剂.
- 这些新型甲衍生物代表了进一步优化为治疗剂的有希望的候选者.
- 这些发现支持对MRGPRX2介导的过敏和炎症性疾病开发新疗法.
相关概念视频
Antiasthma Drugs: Muscarinic Receptor Antagonists
1.8K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.8K
Allergic Drug Reactions
1.5K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.5K
Drug Toxicity: Allergic Reactions
16
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
16
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.9K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.9K
GPCR Desensitization
8.3K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
8.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
15
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
15

